Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The WNT–β-catenin pathway is often overactive in cancer. Can emerging drugs — including stabilized peptides, condensate modulators and degraders — safely and effectively tamp it back down?
Epigenetic editing has emerged as a powerful hit-and-run approach to precise modification of gene expression without altering the underlying DNA sequence. This Review explores the therapeutic potential of epigenetic editing, highlights tools and concepts, assesses challenges and considerations, discusses in vivo studies and examines approaches and agents entering clinical development.
The full potential of pharmacogenomics to improve drug development and clinical practice has yet to be realized. Here, we present recommendations to address barriers to its implementation.
